Current Market Update
πππππππ ππππππ ππππππ – ππππππππππ, πππ ππ π ππππ, πππ ππ π ππππ
The market is cautious but improving: commercial, medical affairs, and regulatory affairs hiring in pharma/biotech is still selective and lean, but demand for experienced, crossβfunctional talent is edging up as pipelines mature into 2026.
πππππππ ππππππ πππππππππππ
US life sciences employment hit a record ~2.1M workers in early 2025, but growth has shifted from big hiring waves to smaller, steadier adds.
β2025-early 2026 looks like βpostβcontraction but not yet boomβ: job openings and hires are up monthβoverβmonth into January 2026, but still below last yearβs levels.
Across healthcare and life sciences, employers are laserβfocused on efficiency, filling fewer roles, faster, and with tighter specs, rather than broad expansion.
ππππππππππ (πππππ, πππππππππ, ππππππ ππππππ, πππ.)
Companies have pulled back from big primaryβcare style sales buildouts and are prioritizing smaller, highly skilled teams around complex launches and specialty/rare assets.
Demand is strongest for people who sit at the intersection of strategy and evidence: market access, pricing, HEOR, and value communication roles are clear priorities for biopharma going into 2026.
Nonclinical βcorporateβ roles (which include many commercial and access positions) currently give candidates a slight advantage: openings and applications are both up monthβoverβmonth, but hires are lagging, so strong profiles can still command attention.
What This Feels Like in Searches
More backfills and βsurgicalβ hires than netβnew headcount.
Heavy emphasis on payer fluency, launch experience, and ability to work crossβfunctionally with medical, regulatory, and HEOR.
Contract and interim roles playing a bigger part in coverage for launch and project work.
πππππππ ππ
π
ππππ
Medical affairs remains one of the more resilient areas versus pure R&D or early discovery; it is central to communicating value and navigating stricter evidence and payer expectations.
Companies are leaning on leaner but more senior teams of MSLs and medical directors who can cover larger geographies/portfolios and plug into realβworld evidence, HEOR, and access discussions.
Hybrid and remoteβheavy models remain common for headquarters medical roles, with field medical still traveling but often covering multiple indications or assets.
What This Feels Like in Searches
Strong demand for people who can partner tightly with commercial while staying compliant: launch medical, evidence generation, and KOL strategy.
Fewer junior MSL openings; more emphasis on candidates who can operate as strategic partners and βplayerβcoaches.β
ππππππππππ ππ
π
ππππ
Regulatory is still viewed as a βmustβhave, not optionalβ function; even as companies run lean, they rarely compromise on key Regulatory Affairs headcount.
Survey data from late 2025 show mixed confidence among regulatory professionals and fewer openings than the prior year, but executives overwhelmingly indicate they do not plan to reduce regulatory hiring because of macro uncertainty or evolving FDA rules.
As pipelines move toward pivotal trials and filings, specialized regulatory (CMC, global, labeling, expedited pathways) is expected to tighten fast as 2026 progresses.
What This Feels Like in Searches
Longer timeβtoβfill and very candidateβselective processes; companies will wait for the right strategic hire.
More competition among candidates for each opening, but also a clear willingness to pay for deep experience that can deβrisk approvals and inspections.
2026 ππππππππππ ππ. 2024β2025
2024β2025 created a temporary surplus of talent due to funding pressure and restructurings, but the underlying need for experienced commercial, medical, and regulatory people never disappeared.
As capital slowly returns and programs move into later stages, demand for these βbridge to marketβ roles should pick up, with parts of the market tilting back toward candidateβfriendly conditions by midβ2026, especially in complex specialties and for senior hires.
The macro signal: early 2026 healthcare hiring shows rising openings and applications with a more modest rise in hires, suggesting employers are still cautious but starting to lean back into growth where revenue and regulatory milestones are on the line.